Literature DB >> 10028526

The development of murine cerebral malaria does not require nitric oxide production.

N Favre1, B Ryffel, W Rudin.   

Abstract

Nitric oxide (NO) production has been suggested to be required for the development of cerebral malaria. However, the importance of this molecule for the appearance of this pathology is debated. To assess whether murine cerebral malaria is NO dependent, we investigated the course of blood-stage Plasmodium berghei ANKA (PbA) infections in inducible nitric oxide synthase (iNOS)-deficient mice. Parasitaemia, haematological alterations, survival and development of cerebral malaria were not affected by the lack of iNOS. To exclude a role of NO produced by other NOS, controls included NO suppression by oral administration of aminoguanidine (AG), a NOS inhibitor. As in iNOS-deficient mice, no difference in the parasitaemia course, survival and haematological values was observed after AG treatment. Our results indicate that NO production is not a crucial factor for the development of murine cerebral malaria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10028526     DOI: 10.1017/s0031182098003606

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  9 in total

1.  Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale.

Authors:  Michael Hawkes; Robert Opika Opoka; Sophie Namasopo; Christopher Miller; Andrea L Conroy; Lena Serghides; Hani Kim; Nisha Thampi; W Conrad Liles; Chandy C John; Kevin C Kain
Journal:  Med Hypotheses       Date:  2011-07-13       Impact factor: 1.538

Review 2.  Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.

Authors:  Robert A Floyd; Hugo C Castro Faria Neto; Guy A Zimmerman; Kenneth Hensley; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2013-02-16       Impact factor: 7.376

3.  Phagocyte-derived reactive oxygen species do not influence the progression of murine blood-stage malaria infections.

Authors:  S M Potter; A J Mitchell; W B Cowden; L A Sanni; M Dinauer; J B de Haan; N H Hunt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

Review 4.  Genetic analysis of cerebral malaria in the mouse model infected with Plasmodium berghei.

Authors:  Sabrina Torre; David Langlais; Philippe Gros
Journal:  Mamm Genome       Date:  2018-06-19       Impact factor: 2.957

Review 5.  The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology.

Authors:  K Artavanis-Tsakonas; J E Tongren; E M Riley
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

6.  Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy.

Authors:  Patricia A Reis; Clarissa M Comim; Fernanda Hermani; Bruno Silva; Tatiana Barichello; Aline C Portella; Flavia C A Gomes; Ive M Sab; Valber S Frutuoso; Marcus F Oliveira; Patricia T Bozza; Fernando A Bozza; Felipe Dal-Pizzol; Guy A Zimmerman; João Quevedo; Hugo C Castro-Faria-Neto
Journal:  PLoS Pathog       Date:  2010-06-24       Impact factor: 6.823

7.  Experimental Models of Microvascular Immunopathology: The Example of Cerebral Malaria.

Authors:  Fatima El-Assaad; Valery Combes; Georges Er Grau
Journal:  J Neuroinfect Dis       Date:  2014-01-06

Review 8.  Vascular dysfunction as a target for adjuvant therapy in cerebral malaria.

Authors:  Leonardo José de Moura Carvalho; Aline da Silva Moreira; Cláudio Tadeu Daniel-Ribeiro; Yuri Chaves Martins
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-08       Impact factor: 2.743

9.  Dexamethasone increased the survival rate in Plasmodium berghei-infected mice.

Authors:  Danilo Reymão Moreira; Ana Carolina Musa Gonçalves Uberti; Antonio Rafael Quadros Gomes; Michelli Erica Souza Ferreira; Aline da Silva Barbosa; Everton Luiz Pompeu Varela; Maria Fani Dolabela; Sandro Percário
Journal:  Sci Rep       Date:  2021-01-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.